Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancer

23 Apr 2025

Abstract excerpt

Current treatments for advanced prostate cancer (PCa) primarily target the androgen receptor (AR) pathway. However, the emergence of castration-resistant prostate cancer (CRPC) and resistance to AR pathway inhibitors (APPIs) remains ongoing challenges. Here, we present BSJ-5-63, a proteolysis-targeting chimera (PROTAC) targeting cyclin-dependent kinases (CDKs) CDK12, CDK7, and CDK9, offering a multipronged...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to PARP inhibition in cancer therapy
Share to Prostate Cancer Treatment and Research
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40267193
DOI: 10.1126/sciadv.adu0847

Provenance

PubMed metadata and Literature Corpus relationships.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Acute BRCAness induction and AR pathway blockage through CDK12/7/9 degradation enhances PARP inhibitor sensitivity in prostate cancerPMID 40267193Read ↗

PROTACs in the Management of Prostate Cancer.Semantic proximity Read ↗

PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancerSemantic proximity Read ↗

Rucaparib - drug evaluation: a PARP inhibitor for the treatment of BRCA-mutated metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Precision Targets for Intercepting the Lethal Progression of Prostate Cancer: Potential Avenues for Personalized TherapySemantic proximity Read ↗

Alterations in BRCA2 as Determinants of Therapy Response in Prostate Cancer.Semantic proximity Read ↗

Double trouble for prostate cancer: synergistic action of AR blockade and PARPi in non-HRR mutated patientsSemantic proximity Read ↗

Targeting CDK9: a promising therapeutic opportunity in prostate cancerSemantic proximity Read ↗

Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors.Semantic proximity Read ↗

A Peptide-Based PROTAC Degrader of BRCA2 Sensitizes Metastatic Castration-Resistant Prostate Cancer to PARP InhibitionSemantic proximity Read ↗

Prostate cancer and PARP inhibitors: progress and challengesSemantic proximity Read ↗

PARP Inhibitors in Advanced Prostate Cancer in Tumors with DNA Damage SignaturesSemantic proximity Read ↗

Changing the History of Prostate Cancer with New Targeted TherapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.